A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Forte Biosciences (FBRX) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.